Orgenesis Inc. Company profile
About Orgenesis Inc
Orgenesis Inc. is a biotech company operating to unlock the potential of cell and gene therapies (CGTs). The Company is focused on autologous (using the patient’s own cells) therapies with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment. The Company has developed a Point of Care Platform comprised of three components: POCare Therapies, POCare Technologies and POCare Network. Its therapeutic portfolio pipeline is diverse and addresses various clinical needs. POCare Technology uses automated systems across a collaborative POCare Network via a combination of science, technology, engineering and networking.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Orgenesis Inc revenues increased from $5.4M to $28.6M. Net loss before extraordinary items decreased 70% to $13M. Revenues reflect POC Services segment increase from $4.3M to $17.1M, Cell process development services segment increase from $1.1M to $11.5M. Lower net loss reflects Other research and development expenses decrease of 43% to $5.6M (expense).
Equity composition
Common Stock $.001 Par, 4/13, 1.75B auth., 49,617,903 issd. Insider owns approx.50.56% Effective August 31, 2011 effected a 35 to one forward stock split
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)